April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
CD4+CD25IntCD45RO+ T Cells Are Refractory to Glucocorticoid Treatment and Mediate IL-17 Production
Author Affiliations & Notes
  • L. P. Schewitz
    Clinical Science at South Bristol,
    University of Bristol, Bristol, United Kingdom
  • L. B. Nicholson
    Cellular and Molecular Medicine,
    University of Bristol, Bristol, United Kingdom
  • A. D. Dick
    Clinical Science at South Bristol,
    Cellular and Molecular Medicine,
    University of Bristol, Bristol, United Kingdom
  • R. W. Lee
    Clinical Science at South Bristol,
    University of Bristol, Bristol, United Kingdom
    Bristol Eye Hospital, Bristol, United Kingdom
  • Footnotes
    Commercial Relationships  L.P. Schewitz, None; L.B. Nicholson, None; A.D. Dick, Shares revenue from a patent for the use of anti-CD25 Abs in steroid resistant inflammatory diseases, P; R.W. Lee, Shares revenue from a patent for the use of anti-CD25 Abs in steroid resistant inflammatory diseases, P.
  • Footnotes
    Support  National Eye Research Centre Grant RJ4740
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 3595. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      L. P. Schewitz, L. B. Nicholson, A. D. Dick, R. W. Lee; CD4+CD25IntCD45RO+ T Cells Are Refractory to Glucocorticoid Treatment and Mediate IL-17 Production. Invest. Ophthalmol. Vis. Sci. 2009;50(13):3595.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Suboptimal responses to corticosteroid therapy represent a major disease burden across medical specialities. We have previously identified a subpopulation of steroid refractory (SR) CD4+ T cells prevalent in patients with both SR uveitis and SR ulcerative colitis, and demonstrated that the SR phenotype is restricted to CD4+ T cells expressing intermediate levels of the -subunit of the IL-2 receptor (CD25int cells). In experimental models of asthma Th17 cells have also been shown to be SR. Therefore, the purpose of this study was to further refine the SR CD4+CD25int cell phenotype, and in particular to evaluate their potential for generating IL-17.

Methods: : Human PBMCs from 6 healthy volunteers were FACS Vantage sorted into CD4+CD25neg/intCD45RO+/- and cultured with CD3/CD28 beads in the presence of high-dose (10-6M) Dex as previously described. Proliferation was then quantified at day 5 by CFSE dilution. In addition, expression of Th1, Th17 and memory cell markers in each CD4+CD25neg/intCD45RO+/- subset was determined by 9 colour flow-cytometry, both pre-culture and following stimulation with PMA/ionomycin

Results: : Inhibition of proliferation by Dex, quantified as percentage suppression relative to positive control cultures, was significantly greater in CD4+CD25intCD45RO-, CD4+CD25negCD45RO+ and CD4+CD25negCD45RO- cells than in CD4+CD25intCD45RO+ cells (p=0.05). Pre-culture, these SR CD4+CD25intCD45RO+ cells are unactivated (CD62Lhigh), 69.7% central memory (CCR7+,CD27+) and do not express IL-17 or IFNγ. However, following culture with PMA/ionomycin 76.7% of the generated IL-17+/ IFNγ - cells arise from the CD4+CD25intCD45RO+ predominantly CCR7+CD27+ subgroup.

Conclusions: : Further to our previous data, we have further refined the phenotype of SR resistant cells to a CD4+CD25intCD45RO+ subset. Moreover, the propensity for these cells to express IL-17, suggests that they are a potential source of pathogenic SR Th17 cells in human autoimmune diseases such as non-infectious uveitis.

Keywords: immunomodulation/immunoregulation • corticosteroids • flow cytometry 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×